Ignite Creation Date:
2024-05-05 @ 10:44 PM
Last Modification Date:
2024-10-26 @ 10:23 AM
Study NCT ID:
NCT01175200
Status:
COMPLETED
Last Update Posted:
2012-07-04
First Post:
2010-08-03
Brief Title:
Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction
Sponsor:
Ascopharm Groupe Novasco
Organization:
Ascopharm Groupe Novasco
Study Overview
Official Title:
Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction A Prospective Mono-center Placebo- and Active Treatment-controlled Randomized Cross Over Study
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DOSAPI
Brief Summary:
This study will establish the optimal therapeutic strategy for patients with a coronary artery disease CAD and chronically treated with clopidogrel 75 mgday requiring co-administration of an anti-platelet treatment with P2Y12 antagonist and a PPI for treatmentprevention of GI ulceration
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None